Core Viewpoint - The company has noted the approval of a generic version of its patented product Budesonide Enteric-Coated Capsules (Nafacon®) by the National Medical Products Administration of China, while emphasizing the protection of its original product under a valid patent until May 7, 2029 [1] Group 1 - The company holds a valid patent (ZL200980127272.5) for Nafacon® in China, which is registered on the national drug patent information platform [1] - According to Chinese patent law, any entity or individual must not manufacture, use, promise to sell, or import products within the patent protection scope without the company's permission before the patent expires, or it will constitute patent infringement [1] - The company reserves the right to take legal action against any infringement of the patent rights and commitments made by generic drug applicants [1] Group 2 - The company is committed to introducing breakthrough therapies to China to meet significant medical needs, highlighting the importance of a robust patent protection system for the sustainable accessibility of innovative drugs [2] - The improving intellectual property protection environment in China's pharmaceutical industry provides strong support for innovation and healthy industry development [2] - The company aims to continue collaborating with various parties to respect and uphold intellectual property rights, fostering a fair competitive environment for the ongoing development of innovative drugs [2]

Group 1 - The board of directors of the company noted the approval of a generic version of its patented product Budesonide Enteric-Coated Capsules (耐赋康®) by the National Medical Products Administration of China [1] - The original product is protected by patent ZL200980127272.5, which is valid until May 7, 2029, and the company has registered this information on the Chinese drug patent information registration platform [1] - According to Chinese patent law, any entity or individual must not manufacture, use, promise to sell, or import products within the patent protection scope without the company's legal permission before the patent expires, or it will constitute patent infringement [1] Group 2 - The company is committed to introducing breakthrough therapies to China to meet urgent medical needs, emphasizing the importance of a robust patent protection system and effective regulations for the sustainable accessibility of innovative drugs [2] - The environment for intellectual property protection in China's pharmaceutical industry has been continuously optimized, providing strong support for pharmaceutical innovation and healthy industry development [2] - The company will continue to collaborate with various parties to respect and uphold intellectual property rights, adhere to relevant laws and regulations, and foster a fair competitive environment to promote the ongoing development and accessibility of innovative drugs for the benefit of Chinese patients [2]

Group 1 - The company has noted the approval of a generic version of its proprietary product Budesonide Enteric-Coated Capsules (Nafukang) by the National Medical Products Administration of China [1] - The original product Nafukang is protected by patent ZL200980127272.5, which is valid until May 7, 2029, and the company has registered this patent information on the Chinese drug patent information registration platform [1] - According to Chinese patent law, any entity or individual must not manufacture, use, promise to sell, sell, or import products that fall under the patent protection without the company's legal permission before the patent expires, or it will constitute patent infringement [1] Group 2 - The company is committed to introducing breakthrough therapies to China to meet urgent medical needs, emphasizing the importance of a robust patent protection system and effective regulations for the sustainable accessibility of innovative drugs [2] - The environment for intellectual property protection in China's pharmaceutical industry has been continuously optimized, providing strong support for pharmaceutical innovation and healthy industry development [2] - The company will continue to collaborate with various parties to respect and uphold intellectual property rights, adhere to relevant laws and regulations, and foster a fair competitive environment to promote the ongoing development and accessibility of innovative drugs for the benefit of Chinese patients [2]